February 20, 202410:00 AM - 11:15 AM PT
Assessment of Needs
The management and treatment of patients with HIV constantly evolves as new data are presented at conferences and published in scholarly journals. This webinar summarizes current and new data on the HIV epidemic, including data from recent clinical trials and updates from recent conferences. Topics include the management of people with HIV, the prevention and management of opportunistic infections, and non-AIDS-related complications of HIV, such as cancer, cardiometabolic disease, and weight gain.
On completion of this activity, learners will be able to:
- Describe progress made toward ending the HIV epidemic, including trends in new infections and the new United States Preventive Services Task Force guidelines for preexposure prophylaxis (PrEP) guidelines and the metabolic effects of PrEP
- Describe new data on the management of treatment-naïve and experienced patients
- Summarize data on the prevention and management of opportunistic infections, such as syphilis, human papillomavirus, and tuberculosis meningitis
- Describe recent data on the management of non-AIDS-related complications of HIV disease, such as cancer, cardiometabolic disease, and weight gain
- Incorporate current COVID-19 oral antiviral agents into the treatment of their patients and describe the current data on post-acute sequelae and vaccine efficacy in those who are immunocompromised
Who Should Attend
This webinar is designed for clinical decision-makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, and other health care professionals.
Individual registration is required in order to receive CME credit or a certificate of participation.
Registration closes on Tuesday, February 20, 2024, 10:30 AM (PT).
For more information or questions, please contact the registration department at firstname.lastname@example.org or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.
The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.
Dr Bedimo reported receiving research grants/grants pending awarded to his institution from Merck & Co, Inc, and serving on the scientific advisory board for Merck & Co, Inc, ViiV Healthcare, Gilead Sciences, Inc., Shionogi, and Janssen Pharmaceuticals. (Updated November 22, 2023)
Dr Benson reported receiving research grants awarded to her institution from Gilead Sciences, Inc, and serving as a consultant to NDA Partners, LLC. (Updated November 2, 2023)
The financial relationships of the COW Board can be found here: https://www.iasusa.org/activities/cases-on-the-web/about-cows/cow-webinars-editorial-board/
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABIM MOC Points
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. IAS-USA, the CME activity provider, will submit your participant information (eg, name, date of birth, activity credits earned, ABIM MOC number) to ABIM through the PARS system for the purpose of reporting ABIM MOC credits.
Educational Review Systems is an approved approver of continuing nursing education by the ASNA, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.25 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California (Provider # 14692), the state of Florida and the District of Columbia.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the session who complete the evaluation and provide accurate NABP e-Profile information will have their credit for 1.25 contact hours (0.125 CEU) submitted to CPE Monitor as early as 14 days after the event and no later than 60 days after the event. Please know that if accurate e-Profile information is not provided within 60 days of the event, credit cannot be claimed after that time. The participant is accountable for verifying the accurate posting of CE credit to their CPE Monitor account within 60 days.
UAN # 0761-9999-24-019-L01-P
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc.
Merck & Co, Inc.
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at email@example.com or 415-544-9400.